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Rituximab in a risk-adapted treatment strategy gives excellent
therapeutic results in nodular lymphocyte-predominant
Hodgkin lymphoma
Nodular lymphocyte-predominant Hodgkin lymphoma
(NLP-HL) is a rare variant of Hodgkin lymphoma, histologi-
cally characterized by prominent lymphocytic proliferation
mixed with histiocytes that form at least a partially nodular
pattern. Due to its rarity, this type of lymphoma still lacks
consolidated and widely accepted treatment guidelines. Cur-
rent first-line therapy approaches are often based on radio-
therapy (RT) alone for non-bulky early-stage NLP-HL, while
chemotherapy regimens [ABVD (doxorubicin, bleomycin,
vinblastine, dacarbazine) or CHOP (cyclophosphamide, dox-
orubicin, vincristine, prednisolone)] plus RT have been
widely used for the most advanced stages (Eichenauer et al,
2014; Hoppe et al, 2015). The observation that malignant
lymphocytes of NLP-HL, although negative for CD15 and
CD30, consistently express CD20 (Hartmann et al, 2014),
provides the rationale for the inclusion of anti-CD20 anti-
body rituximab in the treatment of this disease as a low toxic
component for replacing chemotherapy and/or RT.
Therefore, the outcome and side effects of 12 consecutive
patients with newly diagnosed NLP-HL, who were treated in
our Institution using a risk-adapted, rituximab-based proto-
col, were compared with those of a historical cohort of NLP-
HL patients, previously treated with a conventional modality
approach, i.e. chemotherapy and/or RT (Table I). The clini-
cal features of these two groups of patients were similar(see
Supplementary data), except that the rituximab group pre-
sented more sub-diaphragmatic disease (P = 001) and the
historical cohort included more patients with bulky disease
(P = 003), thus balancing adverse prognostic factors (see
Table SI). All 24 patients showed the typical CD20 positive
stain in at least 30% of tumour cells without either CD15 or
CD30 reactivity (Swerdlow et al, 2008). Comparing the treat-
ments in the two series, 9 historical patients, and no patients
of the rituximab group, underwent involved-field (IF)RT;
cytotoxic agent administration was spared in 42% of the
patients of the rituximab group (Table I). At final restaging,
23 of the 24 patients (958%) were in complete remission
[CR; (Cheson et al, 2007)], while one historical patient
showed refractory disease and was underwent rescue therapy.
Patients who received rituximab-based risk-adjusted therapy
showed excellent response to the treatment and had better
progression-free survival (PFS, P = 004) but not overall sur-
vival (OS) than those of the historical cohort (see Figure S1).
Indeed, during follow-up (median 43 years; range, 05–82
in the whole cohort), four patients, all belonging to the his-
torical cohort and treated with ABVD  IFRT, showed
refractory (n = 1) or recurrent disease (n = 3). These results
confirm that NLP-HL, despite a more indolent clinical beha-
viour than classical HL, may show late multiple relapses after
conventional therapy particularly in advanced stage patients.
Therefore, there is a need for novel treatment approaches
that, along with low toxicity, have an increased efficacy to
improve the overall prognosis.
In our more recent series of NLP-HL patients, the use of
rituximab as single agent in the induction phase was
restricted only to stage I and II patients without risk factors.
However, in order to minimize the possibility of relapses, we
prolonged the anti-CD20 antibody treatment, with eight fur-
ther infusions (once every 3 months) distributed over a 2-
year maintenance therapy in these patients with early favour-
able disease. Therefore, as seen in indolent non-Hodgkin lym-
phoma, the use of rituximab-maintenance in early favourable
NLP-HL seems to delay or avoid relapse. In the remaining
patients, according to a risk-adapted treatment approach,
rituximab therapy was combined with polychemotherapy, giv-
ing a total of four cycles of ABVD to patients with stages I or
II disease but with ≥1 risk factors (early unfavourable) and
six cycles of ABVD to those who presented with advanced
stages (Fig 1). Importantly, the inclusion of rituximab in this
therapeutic scheme appears to provide long-term protection
from relapse when compared with the classical chemo-radio-
therapy. Notably, we observed a higher rate of grade 3–4 neu-
tropenia in the historical cohort (54%) than the rituximab
group (10%; P = 0009); non-haematological toxicity was
recorded only in the historical cohort and was prevalently
RT-related (4/8 thyroid disease, 2/8 lung fibrosis and 2/8
osteoarthritic degeneration). Over the study period, one
patient died due to bleomycin-induced pneumonitis following
the last cycle of R-ABVD. These results underscore the role of
anti-CD20 antibody in NLP-HL, which provides substantial
benefit to many patients, avoiding the need for RT and cyto-
toxic agent treatment or, at least, potentially delaying the
need for both, in those with early favourable stage disease. In
the recent study by Advani et al (2014), rituximab was given
as single agent once per week for 4 weeks to early-stage NLP-
HL patients, giving an overall response rate (ORR) of 100%
with a 67% CR rate. The last 16 patients also had received a
maintenance phase with rituximab (MR) once per week for
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4 weeks every 6 months for 2 years (R + MR). In previously
untreated patients, the median PFS for the R and R + MR
regimens was 19 and 56 years, respectively; progression
occurred in 8 of 12 patients treated with R and in 5 of 9
patients treated with R + MR (Advani et al, 2014). In this
trial, however, the early-stage group also included those
patients with risk factors (Eich et al, 2010).
Our results underline the importance of therapy stratifica-
tion on the basis of risk at baseline and indicate that patients
with risk factors deserve chemotherapy while, for those
patients with very limited stage disease, prolonged exposure to
rituximab is sufficient to guarantee long lasting protection
against disease recurrence. Indeed, when therapy with ritux-
imab as single agent was given in only four weekly doses within
1 month, despite an initial impressive ORR of 100% with CR
observed in 24 of the 28 patients, short rituximab exposure
appears to be insufficient to preclude the likelihood of contin-
uous early relapses as indicated by PFS rates of 964%, 853%
and 814% at 12, 24 and 36 months, respectively and 25% of
total disease recurrences observed in the study (Eichenauer
et al, 2015).
In conclusion, front-line rituximab treatment when fol-
lowed by a 2-year maintenance therapy seems to have a low
toxicity and a high efficacy in treating patients with early stage
NLP-HL without risk factors, replacing chemotherapy and/or
RT schemes. Furthermore, the combination of anti-CD20 anti-
body with the classical ABVD schedule within a risk-adjusted
treatment strategy may be used in the therapeutic approach of
patients with NLP-HL with more advanced stages, sparing tox-
icity derived from the use of RT.
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Fig 1. Scheme of risk-adapted, rituximab-based protocol used in the most recently treated patients with newly diagnosed Nodular lymphocyte-
predominant Hodgkin lymphoma (n = 12). The five patients with early favourable disease, i.e. Stage I or II without risk factors, received an
induction treatment consisting of four weekly administrations of rituximab (375 mg/m2 i.v.), followed by a 2-year maintenance phase in which
rituximab (375 mg/m2 i.v.) was administered once every 3 months. The two patients with early unfavourable stage, i.e. Stage I or II with at least
one risk factor, were treated with rituximab (375 mg/m2 i.v. once per month for four consecutive months, on day 1, plus 4 cycles of ABVD).
The remaining five patients with advanced stage (Stage III or IV) received rituximab (twice per month, on days 1 and 15, for 6 consecutive
months; 375 mg/m2 i.v.) plus 6 cycles of ABVD. ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; R, rituximab.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Fig S1. Kaplan-Meier curves of progression-free survival
per treatment schedule.
Table SI. Patient and tumor characteristics.
Data S1. Supplementary data.
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Clinicopathological characteristics, outcomes and pattern of
mutations in patients with follicular lymphoma who
progressed on Bruton tyrosine kinase inhibitors
Ibrutinib and acalabrutinib (Byrd et al, 2015) are Bruton tyr-
osine kinase (BTK) inhibitors (BTKi) that have revolution-
ized the treatment of patients with different lymphoid
cancers. The survival of patients with lymphoid cancers who
progressed after ibrutinib therapy is poor (Jain et al, 2015;
Martin et al, 2016) and is dependent upon disease character-
istics and the cause of discontinuation. However, the survival
of patients with follicular lymphoma (FL) after discontinuing
BTKi has never been reported. Mechanisms of ibrutinib
resistance are under exploration (Ahn et al, 2017). C481S,
T474I and L528W mutations in BTK and activating
mutations in phospholipase-gamma-2 (PLCG2) are consid-
ered to be primary mechanisms of ibrutinib resistance (Chi-
ron et al, 2014; Burger et al, 2016). It remains unknown
whether patients with FL who progress on BTKi therapy also
exhibit BTK mutations, although recurrent mutations in the
B cell receptor signalling pathway, upstream of BTK, have
been reported in patients with FL (Krysiak et al, 2017).
We evaluated the characteristics and the pattern of muta-
tions in patients with FL who progressed on BTKi by analys-
ing patients with FL enrolled in clinical trials with BTKi at
our institution between 2013 and 2016. Of 60 patients we
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